JP7008886B1 - レバミピドまたはその塩および高分子を含有する水性懸濁液 - Google Patents

レバミピドまたはその塩および高分子を含有する水性懸濁液 Download PDF

Info

Publication number
JP7008886B1
JP7008886B1 JP2021552929A JP2021552929A JP7008886B1 JP 7008886 B1 JP7008886 B1 JP 7008886B1 JP 2021552929 A JP2021552929 A JP 2021552929A JP 2021552929 A JP2021552929 A JP 2021552929A JP 7008886 B1 JP7008886 B1 JP 7008886B1
Authority
JP
Japan
Prior art keywords
aqueous suspension
rebamipide
polyvinylpyrrolidone
mucosta
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552929A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021199813A1 (https=
Inventor
嘉子 川島
昌宏 河畑
直樹 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of JPWO2021199813A1 publication Critical patent/JPWO2021199813A1/ja
Priority to JP2022001605A priority Critical patent/JP7144630B2/ja
Application granted granted Critical
Publication of JP7008886B1 publication Critical patent/JP7008886B1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021552929A 2020-03-31 2021-02-26 レバミピドまたはその塩および高分子を含有する水性懸濁液 Active JP7008886B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022001605A JP7144630B2 (ja) 2020-03-31 2022-01-07 レバミピドまたはその塩および高分子を含有する水性懸濁液

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020062251 2020-03-31
JP2020062251 2020-03-31
PCT/JP2021/007362 WO2021199813A1 (ja) 2020-03-31 2021-02-26 レバミピドまたはその塩および高分子を含有する水性懸濁液

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022001605A Division JP7144630B2 (ja) 2020-03-31 2022-01-07 レバミピドまたはその塩および高分子を含有する水性懸濁液

Publications (2)

Publication Number Publication Date
JPWO2021199813A1 JPWO2021199813A1 (https=) 2021-10-07
JP7008886B1 true JP7008886B1 (ja) 2022-01-25

Family

ID=77930317

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021552929A Active JP7008886B1 (ja) 2020-03-31 2021-02-26 レバミピドまたはその塩および高分子を含有する水性懸濁液
JP2022001605A Active JP7144630B2 (ja) 2020-03-31 2022-01-07 レバミピドまたはその塩および高分子を含有する水性懸濁液
JP2022146010A Active JP7721492B2 (ja) 2020-03-31 2022-09-14 レバミピドまたはその塩および高分子を含有する水性懸濁液
JP2025126162A Pending JP2025160362A (ja) 2020-03-31 2025-07-29 レバミピドまたはその塩および高分子を含有する水性懸濁液

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022001605A Active JP7144630B2 (ja) 2020-03-31 2022-01-07 レバミピドまたはその塩および高分子を含有する水性懸濁液
JP2022146010A Active JP7721492B2 (ja) 2020-03-31 2022-09-14 レバミピドまたはその塩および高分子を含有する水性懸濁液
JP2025126162A Pending JP2025160362A (ja) 2020-03-31 2025-07-29 レバミピドまたはその塩および高分子を含有する水性懸濁液

Country Status (2)

Country Link
JP (4) JP7008886B1 (https=)
WO (1) WO2021199813A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022044701A (ja) * 2022-01-24 2022-03-17 参天製薬株式会社 インジェクションブロー成形されたマルチドーズ型点眼容器に収容される水性懸濁液

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103976946A (zh) * 2014-05-20 2014-08-13 广州艾格生物科技有限公司 一种含有水溶性高分子聚合物的瑞巴派特混悬滴眼液及其制备方法
JP2016507469A (ja) * 2013-02-15 2016-03-10 千寿製薬株式会社 抗菌性金属を含有するジフルプレドナートエマルション組成物
JP2016179960A (ja) * 2015-03-24 2016-10-13 ロート製薬株式会社 眼科用組成物
JP2016204359A (ja) * 2015-04-17 2016-12-08 ロート製薬株式会社 医薬製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI363626B (en) 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
CN105878245B (zh) 2015-01-07 2017-12-15 珠海亿胜生物制药有限公司 一种瑞巴派特水悬浮液的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507469A (ja) * 2013-02-15 2016-03-10 千寿製薬株式会社 抗菌性金属を含有するジフルプレドナートエマルション組成物
CN103976946A (zh) * 2014-05-20 2014-08-13 广州艾格生物科技有限公司 一种含有水溶性高分子聚合物的瑞巴派特混悬滴眼液及其制备方法
JP2016179960A (ja) * 2015-03-24 2016-10-13 ロート製薬株式会社 眼科用組成物
JP2016204359A (ja) * 2015-04-17 2016-12-08 ロート製薬株式会社 医薬製剤

Also Published As

Publication number Publication date
JP2025160362A (ja) 2025-10-22
JP7144630B2 (ja) 2022-09-29
JP2022050562A (ja) 2022-03-30
JP2022180452A (ja) 2022-12-06
WO2021199813A1 (ja) 2021-10-07
JP7721492B2 (ja) 2025-08-12
JPWO2021199813A1 (https=) 2021-10-07

Similar Documents

Publication Publication Date Title
TWI898399B (zh) 含有迪夸弗索(Diquafosol)及陽離子性聚合物之眼科用組合物
TW201808289A (zh) 含阿托平之水性組成物
CN112969465B (zh) 抑制软性隐形眼镜变质的眼科用组合物
JP7614069B2 (ja) ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
TW201707710A (zh) 特徵爲用於滴入戴著軟性隱形眼鏡的乾眼症患者的眼睛之乾眼症治療劑
JP2025160362A (ja) レバミピドまたはその塩および高分子を含有する水性懸濁液
JP7218689B2 (ja) 点眼剤
WO2017159586A1 (ja) ドルゾラミドとチモロールと界面活性剤を含有する医薬組成物
JP6903448B2 (ja) ドルゾラミドとブリモニジンを含む医薬組成物
CN103608000B (zh) 含有透明质酸或其盐以及丙二醇的滴眼液
JP2025146955A (ja) 樹脂製容器に充填された銀塩含有眼科用水性組成物
CN105392481B (zh) 两性离子性软性隐形眼镜用眼科用组合物
JP6366583B2 (ja) 両性イオン性ソフトコンタクトレンズ用眼科用組成物
TW202604499A (zh) 填充於樹脂製容器之含銀鹽眼科用水性組合物
WO2022107791A1 (ja) ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液
TW202408473A (zh) 眼科組成物
KR20250064683A (ko) 안구 충혈 완화를 위한 아프라클로니딘을 포함하는 약제학적 조성물
KR20180077719A (ko) 지속성 점안제 조성물
HK40003059B (zh) 含有阿托品的水性组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210906

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220111

R150 Certificate of patent or registration of utility model

Ref document number: 7008886

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250